<DOC>
	<DOCNO>NCT00981669</DOCNO>
	<brief_summary>The purpose study describe safety , tolerability immunogenicity pentavalent rotavirus vaccine produce Butantan Institute .</brief_summary>
	<brief_title>Rotavirus Vaccine Produced Butantan Institute</brief_title>
	<detailed_description>The Brazilian National Immunization Program ( PNI ) introduce oral monovalent vaccine rotavirus infant immunization schedule since 2006 . Its introduction increase Brazilian Ministry Health budget vaccination Brazil free charge . An agreement Path Foundation Butantan Institute make possible transfer technology Butantan Institute produce , reduce cost , pentavalent rotavirus vaccine include rotavirus serotypes frequent Brazil .</detailed_description>
	<mesh_term>Rotavirus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male healthy Age â‰¥1840 year Not take immunosuppressive drug No clinical history gastrointestinal disease surgeries No history cardiac , neurologic , immunologic endocrine disease Normal eligibility laboratory test To willing participate sign informed consent form No participation another clinical trial past 6 month Had receive licensed vaccine within 2 week ( inactivated vaccine ) 4 week ( live vaccine ) prior enrollment study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>brazilian pentavalent rotavirus vaccine</keyword>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>immunogenicity</keyword>
</DOC>